Navigation Links
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Date:10/6/2008

ImClone's state-of-the-art development and commercial manufacturing facility will offer additional capacity for antibodies in development from both companies.

-- Provides important source of growth beginning in period of patent expirations. The acquisition of ImClone will help Lilly meet the challenge posed by patent expirations on several currently marketed products in the middle of the next decade. ERBITUX has significant future growth opportunities, including from potential new indications in first-line head and neck, colorectal and non-small cell lung cancer. Given that three of ImClone's pipeline assets have the potential to be in Phase III testing in 2009, they could also contribute significantly to Lilly's revenue growth during this period, while ImClone's earlier stage assets should help bolster Lilly's late-stage pipeline.

Promising ImClone Pipeline Molecules

-- IMC-1121B is a fully-human monoclonal antibody that targets the VEGF receptor to deprive tumor blood vessels of the nutrients they need for further growth. Phase II studies are underway for metastatic melanoma, renal, liver, ovarian and prostate cancers. Metastatic breast cancer is in Phase III testing, while Phase III testing in gastric cancer may begin in 2009.

-- IMC-A12 is a fully-human monoclonal antibody that targets the insulin- like growth factor-1 receptor (IGF-1R). Phase II testing is underway in breast, prostate, pancreatic, colon, liver and head and neck cancers, as well as sarcoma, with Phase III trials planned in 2009. IMC-A12 has the potential to work with a variety of other targeted agents.

-- IMC-11F8 is a potent, fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR), the same receptor targeted by ERBITUX. It is currently in Phase II studies for metastatic colorectal cancer with one or more Phase III trials planned in 2009.

Terms

Under the terms of the agreement, Lilly (through a wholly-owned subsid
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
2. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
3. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
4. Amylin and Lilly Set Date and Time for Conference Call
5. Lilly Announces Completion of SGX Acquisition
6. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
7. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
8. Lilly Reports Solid Second-Quarter Results
9. Lilly to Acquire SGX Pharmaceuticals
10. Lillys Connelly Appointed to the Presidents Commission on White House Fellowships
11. Lilly Employees from Nearly 50 Nations Participate in Companys First-Ever Global Day of Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... 19 Lightwave Logic, Inc. (OTC Bulletin Board: LWLG ... on the development of electro-optic polymer materials for applications ... today the addition of Anthony J. Cocuzza, PhD to ... in medicinal chemistry and brings a highly developed set ...
... -- What do Saturn and flowers have in common? ... easily recognizable in the natural world. Now, at an ... University of Massachusetts have created a unique set of ... will consistently assemble themselves into these and other complex ...
... FOLD ) announced today that Stephen Bloch, ... from the Company,s Board of Directors effective February 17, ... Amicus, board since 2004. About Amicus Therapeutics ... oral therapeutics known as pharmacological chaperones for the treatment ...
Cached Biology Technology:Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team 2Sophisticated nano-structures assembled with magnets 2Sophisticated nano-structures assembled with magnets 3
(Date:4/17/2014)... available in German . ... protection money demanded of him, he can expect his premises ... as fear of the consequences is enough to make restaurant ... birds, which lay their eggs in other birds, nests. If ... parasites take their revenge by destroying the entire nest. Consequently, ...
(Date:4/17/2014)... Yokahama IPCC meeting painted a stark warning on the ... has a greenhouse effect 32 times that of carbon ... that humic substances act as fully regenerable electron acceptors ... held in wetlands instead of being released to the ... is disrupted it may enter into a vicious cycle ...
(Date:4/17/2014)... Pine forests are chock full of wild animals and ... populations of fungi are churning away in the soil, ... , Despite the vital role these fungi play in ... A Stanford-led team of scientists has generated a genetic ... North America. The work was published this week in ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... friend," and rightly so. Consider, for example, that they never ... us when we arrive home, and provide comfort when we ... have worked with and lived next to humans, which some ... the 400 breeds and varieties are unique, but only one ...
... use of a robot to assist with the most ... patient,s risk of developing a rare but serious complication, ... edition of the Journal of Robotic Surgery. ... School at Houston statistically analyzed operative times, length of ...
... Harbor Laboratory (CSHL) professor David Jackson, Ph.D., and a team ... development of the maize plant, commonly known in the United ... understanding of how the different parts of maize arise--important information ... in the U.S. and a mainstay of the global food ...
Cached Biology News:Lessons from the Iditarod 2Lessons from the Iditarod 3Robotic surgery lowers risk of a rare but serious complication of gastric bypass 2Researchers find an essential gene for forming ears of corn 2
... The epitope recognized by ... of isoform 5 of human ... AAH19917.1 (GeneID 9444). The ... isoforms 1, 2, 3, 4, ...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
...
See product name for description....
Biology Products: